Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosiglitazone in Pituitary Tumors
NCT00616642Phase 2Terminated
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Oct 2006
- Primary completion
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rosiglitazone in Cushing's disease (CD), pituitary adenoma, sponsored by UCLA Jonsson Comprehensive Cancer Center. Started Oct 2006; status: terminated.
02
Drugs
rosiglitazone
03
Conditions
Cushing's disease (CD)pituitary adenoma
Beyond the preview
Go deeper on NCT00616642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00616642.